Inhibrx (NASDAQ:INBX) Earns Market Perform Rating from JMP Securities

Inhibrx (NASDAQ:INBX)‘s stock had its “market perform” rating restated by investment analysts at JMP Securities in a research note issued on Wednesday,Benzinga reports.

Inhibrx Stock Down 3.8 %

INBX opened at $13.09 on Wednesday. The firm’s fifty day moving average price is $14.64 and its two-hundred day moving average price is $14.66. Inhibrx has a 1 year low of $10.80 and a 1 year high of $18.95.

Insiders Place Their Bets

In other news, Director Jon Faiz Kayyem acquired 69,686 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the acquisition, the director now directly owns 51,093 shares of the company’s stock, valued at $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On Inhibrx

A hedge fund recently bought a new stake in Inhibrx stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 22,584 shares of the company’s stock, valued at approximately $348,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management owned 0.16% of Inhibrx at the end of the most recent reporting period. 82.46% of the stock is currently owned by institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.